Pharmaceutical - Xofigo

Filter

Current filters:

Xofigo

Popular Filters

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

15-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) have recommended…

BayerOncologyPharmaceuticalPricingRegulationUKXofigo

Bayer boasts strong R&D pipeline and growth prospects

03-12-2014

German pharma major Bayer gave a spirited presentation of its pipeline candidates in both pharma and…

AdempasBayerEyleaFinancialHematologyOncologyOphthalmicsPharmaceuticalResearchStivargaXareltoXofigo

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

UK’s NICE unable to give the go ahead to new prostate cancer drug Xofigo

24-03-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

BayerNorthern EuropeOncologyPharmaceuticalPricingRegulationUKXofigo

Bayer foresees 8% pa sales growth for pharma through 2016

Bayer foresees 8% pa sales growth for pharma through 2016

13-03-2014

Germany’s Bayer expects strong growth for its pharmaceutical business as a result of a number of new…

AdempasBayerEyleaFinancialPharmaceuticalStivargaXareltoXofigo

Way clear for Bayer to complete Algeta acquisition

26-02-2014

The way is now clear for Germany’s Bayer to acquire Norwegian pharmaceutical company Algeta, under…

AlgetaBayerMergers & AcquisitionsOncologyPharmaceuticalXofigo

Bayer confirms plans to acquire Norway’s Algeta

Bayer confirms plans to acquire Norway’s Algeta

19-12-2013

German drugs and chemicals major Bayer has officially announced its intention to acquire Norwegian pharmaceutical…

AlgetaBayerGermanyMergers & AcquisitionsNorwayOncologyPharmaceuticalXofigo

Norway’s Algeta confirms takeover bid approach from Bayer

Norway’s Algeta confirms takeover bid approach from Bayer

26-11-2013

In response to recent media commentary, the board of directors of Norway’s Algeta this morning confirmed…

AlgetaBayerMergers & AcquisitionsNorwayOncologyPharmaceuticalXofigo

EU approval for Bayer’s prostate cancer drug Xofigo

EU approval for Bayer’s prostate cancer drug Xofigo

15-11-2013

The European Commission has granted marketing authorization for German drug and chemical major Bayer’s…

AlgetaBayerEuropeOncologyPharmaceuticalRegulationXofigo

EMA unit backs approval of Bayer's radium-233

EMA unit backs approval of Bayer's radium-233

20-09-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

AlgetaBayerEuropeOncologyPharmaceuticalradium-223 dichlorideRegulationXofigo

Positive results for Bayer's prostate cancer drug

18-07-2013

German drug major Bayer (BAYN: DE) has announced positive results of a Phase III study of its drug radium…

AlgetaBayerEuropeMen's HealthPharmaceuticalResearchXofigo

First sales of Xofigo triggers 50 million-euro milestone payment to Algeta from Bayer

30-05-2013

Norway's Algeta (OSE: ALGETA) announced today (May 30) that Xofigo (radium Ra 223 dichloride) injection…

AlgetaBayerFinancialMarkets & MarketingNorth AmericaPharmaceuticalXofigo

Fast FDA approval for Bayer's new drug for advanced prostate cancer, Xofigo

16-05-2013

The US Food and Drug Administration yesterday (May 15) approved Xofigo (radium Ra 223 dichloride, initially…

AlgetaAstellas PharmaBayerNorth AmericaOncologyPharmaceuticalRegulationXofigo

Back to top